Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Droller

Showing results (41-50 of 116) with videos related to

Pageof 12
Sort By:
The Journal of Urology|July 29, 1998
Telomerase activity: a biomarker of cell proliferation, not malignant transformationM J Droller
The Urologic Clinics of North America|October 1, 1980
Transitional cell carcinoma: an overviewM J Droller
The Journal of Urology|February 1, 1987
Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acidM J Droller
The Urologic Clinics of North America|November 1, 1992
Treatment of regionally advanced bladder cancer. An overviewM J Droller
The Journal of Urology|September 19, 2000
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude miceM J Droller
The Journal of Urology|February 24, 2001
Markers for recurrence of superficial bladder cancer: what is valid?M J Droller
The Journal of Urology|January 27, 2000
Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasionM J Droller
The Journal of Urology|May 8, 2000
Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trialM J Droller
The Journal of Urology|May 11, 2001
Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypesM J Droller
The Journal of Urology|November 1, 1994
This month in Investigative Urology. A commentary on suramin demonstrates in vitro toxicity against transitional cell carcinoma cell lines and exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinomaM J Droller
Pageof 12

Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
The Journal of Urology|July 29, 1998
Telomerase activity: a biomarker of cell proliferation, not malignant transformationM J Droller
The Urologic Clinics of North America|October 1, 1980
Transitional cell carcinoma: an overviewM J Droller
The Journal of Urology|February 1, 1987
Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acidM J Droller
The Urologic Clinics of North America|November 1, 1992
Treatment of regionally advanced bladder cancer. An overviewM J Droller
The Journal of Urology|September 19, 2000
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude miceM J Droller
The Journal of Urology|February 24, 2001
Markers for recurrence of superficial bladder cancer: what is valid?M J Droller
The Journal of Urology|January 27, 2000
Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasionM J Droller
The Journal of Urology|May 8, 2000
Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trialM J Droller
The Journal of Urology|May 11, 2001
Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypesM J Droller
The Journal of Urology|November 1, 1994
This month in Investigative Urology. A commentary on suramin demonstrates in vitro toxicity against transitional cell carcinoma cell lines and exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinomaM J Droller
Pageof 12